The past decade has witnessed great advances in the treatment of chronic myeloid leukemia (CML), brought about in large part by the development of BCR-ABL tyrosine kinase inhibitors (TKIs). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.